Meeting
2023 ASCO Genitourinary Cancers Symposium
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma.
Authors
David F. McDermott
Beth Israel Deaconess Medical Center, Boston, MA
David F. McDermott , Avivit Peer , Neeraj Agarwal , Michael B. Atkins , Jerry Cornell , Rodolfo F. Perini , Kenneth F. Grossmann , Howard Gurney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05468697
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS747)
DOI
10.1200/JCO.2023.41.6_suppl.TPS747
Abstract #
TPS747
Poster Bd #
N5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).
First Author: David F. McDermott
Poster
2019 Genitourinary Cancers Symposium
An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma.
First Author: Eric Jonasch
Poster
2022 ASCO Annual Meeting
Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.
First Author: Eric Jonasch
Poster
2023 ASCO Annual Meeting
Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.
First Author: Laurence Albiges